Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Search for:

Recent Posts

Bictegravir (Biktarvy®): Positive CHMP Opinion in the EU
Burosumab (Crysvita®): First Global Approval – Infrastructure repair for patients with X-linked hypophosphataemia
Revolution, innovation, and collaboration: report from the World Drug Safety Congress
Baloxavir Marboxil (XOFLUZA™): First Global Approval – a One-Pill Wonder for Patients with Influenza
Apalutamide (Erleada™): First Global Approval – Reduces risk of metastasis in patients with non-metastatic, castration-resistant prostate cancer

Recent Comments

	Revolution, innovati… on Using state-of-the-art technol…
	Durvalumab (IMFENZI®… on Durvalumab (Imfinzi™): First G…
	Inotuzumab ozogamici… on Inotuzumab Ozogamicin (Bespons…
	Ocrelizumab (Ocrevus… on Ocrelizumab (Ocrevus™): First…
	Plecanatide (Trulanc… on Plecanatide (Trulance™): First…

Archives

Categories

Adis (67)
Adis Journals (76)
Adis Pharmacovigilance (20)
AdisInsight (79)
Uncategorized (1)

September 20, 2016 1440 × 599

cropped-drug-evaluation-istock_000015211851large.jpg

Leave a Reply Cancel reply

Powered by WordPress.com.